Rahul Shukla

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)-Raebareli, Lucknow, Uttar Pradesh, India

\*Address all correspondence to: rahulshuklapharm@gmail.com

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**25**

*Pharmacogenomics: Overview, Applications, and Recent Developments*

[10] Crews KR, Hicks JK, Pui CH,

Pharmacogenomics and individualized medicine: Translating science into practice. Clinical Pharmacology and Therapeutics. 2012;**92**(4):467-475

[11] Pirmohamed M. Pharmacogenetics and pharmacogenomics. British Journal of Clinical Pharmacology.

Utomo BB, Parikesit AA. Screening of commercial cyclic peptide as inhibitor NS5 methyltransferase of dengue virus through molecular docking and molecular dynamics simulation. Bioinformation. 2014;**10**(1):23

[12] Tambunan US, Zahroh H,

[13] Tambunan US, Parikesit AA, Prasetia T, Kerami D. In silico molecular interaction studies of suberoylanilide hydroxamic acid and its modified compounds with histones deacetylase class II *Homo sapiens* as curative measure towards cervical cancer. Engineering.

[14] Parikesit AA. Introductory chapter: The contribution of bioinformatics as blueprint lead for drug design. Molecular Insight of Drug Design.

[15] Handa M, Sharma A, Verma RK, Shukla R. Polycaprolactone based nano-carrier for co-administration of moxifloxacin and rutin and its in-vitro evaluation for sepsis. Journal of Drug Delivery Science and Technology.

[16] Weinshilboum R, Wang L.

Pharmacogenomics: Bench to bedside. Nature Reviews. Drug Discovery.

[17] Roses AD. Pharmacogenetics and the practice of medicine. Nature.

2013;**5**(10):203-206

2018;**29**:7

2019;**54**:101286

2004;**3**(9):739-748

2000;**405**(6788):857-865

Relling MV, Evans WE.

2001;**52**(4):345

*DOI: http://dx.doi.org/10.5772/intechopen.93737*

[1] Daly AK. Genome-wide association studies in pharmacogenomics. Nature Reviews. Genetics. 2010;**11**(4):241-246

[2] Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, et al. Evaluation of genetic factors for warfarin dose prediction. Clinical Medicine & Research. 2007;**5**(1):8-16

[3] Wattanachai N, Kaewmoongkun S, Pussadhamma B, Makarawate P, Wongvipaporn C, Kiatchoosakun S, et al. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients. European Journal of Clinical Pharmacology.

[4] Cha PC, Zembutsu H, Takahashi A, Kubo M, Kamatani N, Nakamura Y. A genome-wide association study identifies

[5] Chadwick R, Ten Have H, Meslin EM. The Sage Handbook of Health Care Ethics. Sage Publications; 2011

SNP in DCC is associated with gallbladder cancer in the Japanese population. Journal of Human Genetics.

[6] Alsanosi SM, Skiffington C, Padmanabhan S. Pharmacokinetic pharmacogenomics. In: Handbook of Pharmacogenomics and Stratified

Medicine. 2014. pp. 341-364

[7] Patil J. Pharmacogenetics and pharmacogenomics: A brief introduction. Journal of Pharmacovigilance. 2015;**2**:3-4

2011;**63**(2):437-459

[9] Xie HG, Frueh FW.

Medicine. 2005:325-337

[8] Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacological Reviews.

Pharmacogenomics steps toward personalized medicine. Future

2017;**73**(8):973-980

2012;**57**(4):235-237

**References**

*Pharmacogenomics: Overview, Applications, and Recent Developments DOI: http://dx.doi.org/10.5772/intechopen.93737*
